Mobile App

The Pharmacogenomic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.
 
 * Trends in pharmacogenomic partnering deals
 * pharmacogenomic partnering agreement structure
 * pharmacogenomic partnering contract documents
 * Top pharmacogenomic deals by value
 * Most active pharmacogenomic dealmakers
 * Average pharmacogenomic deal values
 http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/pharmacogenomic-partnering-terms-agreements.html
 
 Description
 The Pharmacogenomic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies. Market Research Companies
 
 The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
 Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
 
 This report contains over 500 links to online copies of actual pharmacogenomic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
 The initial chapters of this report provide an orientation of pharmacogenomic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmacogenomic dealmaking since 2005, including details of average headline, upfront, milestone and royalty terms.
 
 Chapter 3 provides a review of the leading pharmacogenomic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
 Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of pharmacogenomic deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
 Chapter 5 provides a comprehensive and detailed review of pharmacogenomic partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
 The report also includes numerous tables and figures that illustrate the trends and activities in pharmacogenomic partnering and dealmaking since 2007.
 
 In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmacogenomic technologies and products.
 
 Pharmacogenomic Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pharmacogenomic trends and structure of deals entered into by leading companies worldwide.
 
 For more information kindly visit :
 Pharmacogenomic Partnering Terms & Agreements
 
 Or
 
 Bharat Book Bureau
 Tel: +91 22 27810772 / 27810773
 Fax: + 91 22 27812290
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/#!/Sandhya3B